OverviewSuggest Edit

CytoDyn is a biotechnology company developing therapies to address cancer, HIV, and other autoimmune diseases. It provides Leronlimab, a monoclonal antibody, to be used as a platform drug for a variety of indications. The company aims to help patients with breast cancer, HIV, graft-versus-host disease (GvHD), and nonalcoholic steatohepatitis (NASH).
TypePublic
Founded2002
Websitecytodyn.com

Latest Updates

Employees (est.) (Mar 2020)10
Share Price (Mar 2020)$1.4 (+47%)

Cytodyn Financials and Metrics

Cytodyn Revenue

USD

Net income (Q2, 2020)

(14.9m)

EBIT (Q2, 2020)

(12.1m)

Market capitalization (27-Mar-2020)

590.1m

Closing stock price (27-Mar-2020)

1.4

Cash (30-Nov-2019)

409.5k

EV

589.8m
Cytodyn's current market capitalization is $590.1 m.
Annual
USDFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

General and administrative expense

5.5m6.2m3.1m3.3m5.8m6.8m7.3m12.1m

R&D expense

530.0k619.8k4.0m15.2m13.7m20.2m38.2m42.5m

Operating expense total

6.0m6.8m7.1m18.4m19.5m27.0m45.6m54.6m

Depreciation and amortization

352.4k360.6k361.6k366.4k356.1k1.2m
Quarterly
USDQ2, 2012Q3, 2012Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Cost of goods sold

426.1k3.1m

General and administrative expense

1.0m1.1m1.3m1.4m597.3k772.8k916.0k664.5k660.4k750.6k856.7k880.7k2.0m1.4m1.7m1.4m1.6m1.6m2.0m2.0m2.7m3.3m3.0m3.1m

R&D expense

169.2k71.5k161.0k33.4k158.6k542.8k1.7m2.1m2.1m2.3m5.3m1.7m2.7m3.7m4.4m6.5m8.1m9.1m12.1m11.4m12.9m9.0m9.1m8.5m

Operating expense total

1.2m1.1m1.4m1.4m755.9k1.3m2.6m2.7m2.7m3.0m6.2m2.5m4.7m5.1m6.1m7.9m9.7m10.7m14.1m13.4m15.5m12.4m12.1m11.6m
Annual
USDFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

285.0k603.7k4.9m1.1m9.6m1.8m1.2m2.6m

Accounts Receivable

Prepaid Expenses

66.0k139.8k488.8k253.8k207.3k227.2k107.2k

Inventories

Quarterly
USDQ2, 2012Q3, 2012Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

129.8k1.8m1.4m412.0k676.5k10.1m7.4m2.3m2.4m1.7m2.8m3.3m10.2m4.4m8.8m7.8m946.2k1.3m4.9m4.7m772.4k1.6m1.8m409.5k

Accounts Receivable

63.6k

Prepaid Expenses

30.7k36.6k34.0k105.3k141.0k257.5k487.8k398.8k231.2k185.5k260.1k223.9k276.5k338.9k221.8k181.0k294.4k265.7k338.4k200.9k232.5k272.6k623.7k

Current Assets

934.0k2.5m2.0m940.8k1.0m10.5m8.0m2.7m2.8m1.9m3.6m4.1m12.2m7.1m13.6m12.7m4.3m4.7m6.6m7.5m3.9m4.5m3.2m3.2m
USDY, 2019

EV/EBIT

-48.7 x

EV/CFO

-26.8 x

Financial Leverage

-1.3 x
Show all financial metrics

Cytodyn Online and Social Media Presence

Embed Graph

Cytodyn News and Updates

CytoDyn Files FDA-Suggested Modifications to IND and Protocol for Phase 2 Clinical Trial for COVID-19 Patients with Mild to Moderate Indications and a Second Randomized Protocol for All COVID-19 Patients in Severe Condition Will be Filed Next Week per FDA Recommendation

VANCOUVER, Washington, March 27, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that, at the suggestio…

Cytodyn Frequently Asked Questions

  • When was Cytodyn founded?

    Cytodyn was founded in 2002.

  • How many employees does Cytodyn have?

    Cytodyn has 10 employees.

  • Who are Cytodyn competitors?

    Competitors of Cytodyn include Calithera Biosciences, Northwest Biotherapeutics and Merrimack Pharmaceuticals.